Cerebrolysin news and clinical trials

The Expert Council of the National Association of Pediatric Neurologists stratified Cerebrolysin into Group B, representing medications for ADHD with a limited evidence base, to be used only within a multidisciplinary approach.

Researchers published a case report of a 57-year-old man who experienced rapid neurological improvement after receiving adjunctive Cerebrolysin following mechanical thrombectomy for a stroke. The therapy was used to address persistent tissue-level hypoperfusion.

The National Hospital of Acupuncture in Vietnam registered a randomized controlled trial for 440 patients to evaluate the efficacy of combined electroacupuncture, acupressure, and acupoint injections of Cerebrolysin or B-complex vitamins for post-acute ischemic stroke rehabilitation.

A case report describes a 69-year-old man with post-traumatic aphasia who showed significant language improvement after a 21-day course of intravenous Cerebrolysin alongside speech therapy. His Aphasia Quotient rose from 66.2 to 97.1 by day 28.

A narrative review of pharmacological treatments for severe traumatic brain injury examined human evidence for several agents, including Cerebrolysin, and proposed a modular framework for future development. The authors caution against routine off-label polypharmacy.

Clinicians reported on an 88-year-old woman who received Cerebrolysin 30 mL/day as an adjunctive treatment after mechanical thrombectomy for a stroke. Neurological deficits resolved over 24 hours, though the report does not establish the therapeutic efficacy of this short-course intervention.

A systematic review and meta-analysis of 8 studies involving 670 patients found that residual hypoperfusion detected by post-procedural imaging is consistently associated with reduced odds of functional independence after endovascular thrombectomy. The study identified specific perfusion thresholds.

Researchers reported that a 38-year-old stroke patient with Wernicke's aphasia experienced substantial improvements in language and motor function after receiving a 10-day course of Cerebrolysin combined with rehabilitation. This highlights the potential synergistic effects of the therapy.

Clinicians reported a case of a 67-year-old woman with acute basilar artery occlusion who achieved complete neurological recovery by day 3 following mechanical thrombectomy and adjunctive Cerebrolysin therapy. The patient sustained this recovery throughout a 12-month follow-up.

A survey of neurologists across 21 Asian countries or regions identified significant gaps between research evidence and clinical practice regarding the use of post-stroke pharmacological therapies. Usage of treatments like cerebrolysin varies significantly depending on national guideline inclusion.

A study of 402 medical students found that the probability of using synthetic nootropics like Cerebrolysin increases by 1.86 times as university education progresses. The research highlights widespread use of cognitive stimulants among students during periods of academic stress.

Researchers found that exosomes released by Cerebrolysin-treated cerebral endothelial cells restored cellular integrity impaired by fibrin and tPA. This treatment reduced inflammation-related proteins and increased proteins involved in tight junctions and metabolism.

The journal Neurochemical research issued a retraction for a study regarding the effects of Cerebrolysin on nanoparticle-induced pathology.

A cohort study of 340 patients found that adults with moderate traumatic brain injury and nonoperative hemorrhage had improved 6-month survival and better functional outcomes when treated with Cerebrolysin. Survival rates were 59.4% in the treatment group compared to 27.8% in standard care.

A study in Helix pomatia snails showed that the anti-dementia drugs Cerebrolysin and D-cycloserine reversed learning impairments caused by L-kynurenine. The drugs worked by inhibiting kynurenine aminotransferase activity and reducing levels of the memory-impairing metabolite kynurenic acid.

A review published in the Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova discusses how Cerebrolysin, a blend of peptides and amino acids, may accelerate speech recovery when combined with speech therapy after ischemic stroke.

The Journal of Alzheimer's disease issued a retraction for a 2026 study regarding the regional neurogenic effects of CNTF-derived peptides and Cerebrolysin in transgenic mice.

The journal Molecular neurobiology retracted a study on the timed release of Cerebrolysin using titanate nanospheres for Parkinson's disease treatment.

A meta-analysis of 3 observational studies involving 294 patients found that Cerebrolysin as an adjunct to mechanical thrombectomy improved functional outcomes and decreased mortality and symptomatic intracerebral hemorrhage in acute ischemic stroke patients.

The journal Acta neuropathologica retracted a study about the neurotrophic effects of Cerebrolysin in a transgenic model of Rett syndrome.

In a rat model of sciatic nerve damage, researchers found that Cerebrolysin improved functional recovery and promoted axonal regeneration. A dosage of 5 mg/kg was more effective than 2.5 mg/kg at shifting macrophage polarization from pro-inflammatory to pro-healing.

The journal Acta neuropathologica published an expression of concern regarding a study on the neuroprotective effects of Cerebrolysin in mice.

A systematic review and meta-analysis concluded that using Cerebrolysin at doses of 10 ml to 30 ml during post-stroke rehabilitation increases the quantity and quality of restored functions and skills.

In a rat model of middle cerebral artery occlusion, researchers compared three neuroprotectors and found that Mexidol had the most pronounced effect on reducing necrosis volume, while Cerebrolysin showed a less pronounced but similar neuroprotective effect.

Researchers published a pooled analysis in the Journal of clinical neurology regarding Cerebrolysin and the risk of hemorrhagic transformation.

Researchers found that in a cohort of endovascular thrombectomy patients, Cerebrolysin treatment was associated with higher odds of functional independence at 12 months (aOR 6.10, 95% CI 1.64-22.66) compared to controls.

A case report describes a 39-year-old patient with ischemic stroke who showed improvements in motor function and speech regression after receiving intravenous Cerebrolysin at a dose of 20 ml as part of a comprehensive rehabilitation program.

A secondary analysis of the CEREHETIS trial indicates that in high-risk ischemic stroke patients, Cerebrolysin reduced the hazard of symptomatic hemorrhagic transformation (HR 0.245) and allowed for earlier anticoagulation resumption by 1-2 days.

A case report discussed the use of multimodal treatment, including Cerebrolysin, following the surgical excision of a cerebral glioma. The authors suggest that incorporating neuroprotective measures in perioperative management may support recovery in neurosurgical oncology patients.

Researchers published a study identifying 8 brain-penetrant peptides in cerebroprotein hydrolysate oral liquid. The study found these peptides reduce depressive behaviors in mice by upregulating tyrosine hydroxylase expression and increasing norepinephrine levels.

New paper in The International journal of risk & safety in medicine: Use of nootropics in Alzheimer's disease: An analysis of regulatory positions and drug policies in the countries of the Commonwealth of Independent States.